Driven by promises of rapid weight loss, quick injury recovery and anti-ageing, peptide therapy has exploded from underground bodybuilding circles into mainstream suburban wellness.
But beneath the social media hype lies a troubling reality: consumers are stepping outside traditional healthcare to self-inject unapproved "research chemicals", experimenting with compounds whose safety and effectiveness in humans remain uncertain, while some are buying products from grey-market suppliers.
With limited human trials and grey-market vendors profiting off the hype, experts warn consumers are risking their health on unfinished science.
The science vs hype
Beneath the glossy promises of the peptide boom lies a harsh scientific reality: human physiology operates on a level of complexity that a lab dish cannot replicate.
Compounds such as BPC-157 and TB-500 have earned near-mythic status on social media, where users share glowing reviews of erased wrinkles and healed tendons.
Yet when medical researchers analyse the data, the foundation is strikingly thin.
The majority of compelling data comes from cell-culture experiments or rodent models.
"Three gaps separate a petri dish or a rat cage from a human body," explains award-winning professor Tricia Naicker, a medicinal chemist in the Discipline of Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN).
Naicker points out that dose and exposure do not scale linearly from rodents to humans.
A concentration that nudges a cell in a lab dish is fundamentally different from what is safe inside a complex human circulatory system.
Furthermore, rodent studies rely on young, healthy, genetically uniform animals, nothing like the diverse, ageing, multi-condition humans actually buying these products.
"Immunogenicity is most overlooked," Naicker warns.
Immunogenicity is the ability of a foreign substance, such as an antigen, to trigger an adaptive immune response in the body.
"Peptides are small proteins, and the human immune system is very good at recognising foreign proteins and mounting a response, sometimes silently reducing effectiveness over repeated doses, sometimes triggering allergic or autoimmune-type reactions that never show up in a two-week mouse study.
"This is why regulators require phased human trials: Phase I to catch basic safety signals, Phase II for dosing and early efficacy, Phase III for rare adverse events across large, diverse populations.
"Skipping from 'it worked in mice' straight to self-injection skips the steps designed to catch what mice can't tell you."
The confusion often stems from treating all peptides as equal, when in reality the clinical evidence varies enormously.
"Terminology can become confusing because 'peptide' describes a chemical class rather than a particular level of safety or evidence," says lecturer Nurit Dahan-Farkas from the Department of Pharmacy and Pharmacology at the University of the Witwatersrand (Wits).
"There are peptides with substantial clinical evidence and regulatory approval, such as semaglutide and peptide-based drug tirzepatide. There are also investigational or less-established compounds such as BPC-157, TB-500, CJC-1295 and ipamorelin marketed for weight loss, recovery or anti-ageing.
"The critical issue is that being sold as a peptide, being chemically tested, and having demonstrated clinical efficacy and safety are three very different things", says Dahan-Farkas.
Retatrutide
Even for compounds backed by late-stage clinical trials, consumers are jumping the gun. A prime example is Retatrutide, an investigational peptide generating massive interest for obesity and metabolic disease.
"It is a triple agonist, acting on the GIP, GLP-1 and glucagon receptors. This is different from medicines such as semaglutide, which primarily act only through the GLP-1 receptor," Dahan-Farkas explains.
"The clinical trial data to date have generated considerable interest, however, Retatrutide is still investigational and has not been approved by the FDA."
Dahan-Farkas cautions against doctors "raving about" or prescribing retatrutide.
"Until the appropriate Phase III evidence and regulatory review have been completed, I would be cautious about routine prescribing outside properly governed clinical research.
"FDA approval is based not simply on whether a drug produces impressive results, but on the overall assessment of efficacy, safety, manufacturing quality, dosing, long-term outcomes and the benefit-risk profile," says Dahan-Farkas.
Bypassing safety monitoring to get investigational drugs early carries blind spots. While late-stage trial results look promising, Naicker warns that rare side effects occurring in 1 in 50,000 people only surface after years of real-world use.
Beyond potential organ toxicity and other poorly understood effects, Naicker warns of unmapped drug interactions.
"Nobody has studied what happens when an unapproved peptide is combined with prescription medications, existing conditions, or other stacked injectables. Grey-market buyers are betting that the risks regulatory trials are specifically designed to catch simply won't apply to them," says Naicker.
Even cosmetic peptides like GHK-Cu show modest clinical benefits in topical creams, but Naicker stresses that wellness marketing wildly inflates the science behind them.
"The speculative leap happens when extrapolating from 'topical cream improves skin appearance' to 'injectable GHK-Cu extends lifespan or reverses aging systemically'."
The shift to the mainstream
How did self-injection transform from a gym-bro stereotype into mainstream middle-class wellness?
Botox, insulin and testosterone replacement therapy (TRT) quietly laid the psychological runway. Decades of routine cosmetic and medical maintenance normalised the needle.
Naicker notes that telehealth TRT clinics normalised self-injection for suburban buyers, and the rise of GLP-1 weight-loss drugs transformed peptide pens into an aspirational wellness tool.
Simultaneously, a credibility inversion occurred online.
"Social media created an always-on marketplace for appearance and anti-ageing advice, where algorithms reward confidence over careful science. Today, someone with a ring light and a testimonial carries more persuasive weight than a PhD with a stack of honest data."
South Africa is already seeing the peptide boom
South Africa is not on the sidelines of the global peptide boom.
In May, the South African Health Products Regulatory Authority (SAHPRA) warned of a growing increase in unregistered peptide products being sold online, in gyms and through informal channels.
SAHPRA said the products are being promoted for weight loss, muscle growth, anti-ageing, injury recovery, improved concentration and enhanced performance. Among the peptides identified by the regulator were BPC-157, TB-500, CJC-1295 and ipamorelin which are several of the same compounds gaining attention in international wellness and bodybuilding communities.
The regulator warned that these products have not been evaluated and approved by SAHPRA for safety, quality or efficacy. It urged consumers to be cautious about products obtained online or through unverified suppliers and to consult a registered healthcare professional if they are unsure about a product.
The warning comes against a broader crackdown on unregistered injectable medicines in South Africa. In May, SAHPRA and the South African Pharmacy Council (SAPC) announced enforcement action against the unlawful manufacture and distribution of unregistered GLP-1 and GIP medicines containing semaglutide, tirzepatide, or combinations of the two. The regulators said these products were being manufactured outside the legal framework governing the compounding of medicines.
SAHPRA has also warned that medicines obtained outside the legitimate supply chain may contain no active ingredient, the wrong active ingredient, dangerous levels of an ingredient or harmful inactive ingredients, and may be non-sterile and contaminated with microbes.
The ticking public health time bomb
Beyond whether the molecule works, the real danger is what lurks inside an unregulated vial.
"A 'research chemical' is manufactured, labeled and shipped with zero requirement for pharmaceutical-grade purity, sterility or accurate dosing," Naicker warns.
She points out that genuine Active Pharmaceutical Ingredients (APIs) undergo strict Good Manufacturing Practice (GMP) standards, including endotoxin testing, heavy-metal screening and batch verification.
Skipping this process exposes buyers to the possibility of contaminated, improperly dosed or degraded products.
"Peptides are fragile molecules that degrade with heat, light and time; a vial that sat in a hot delivery truck or a mailbox for a few days can arrive already degraded or contaminated with no visible sign of it," Naicker adds.
Dahan-Farkas echoes this concern, "I would be particularly cautious especially where there is no reliable information about manufacturing standards, sterility, dose accuracy, contaminants, or long-term safety."
Self-injecting users face potential risks from contaminated products, underdosing or severe overdosing.
"The molecular story behind these peptides is fascinating, but 'biologically plausible' and 'clinically proven safe' are separated by years of trials designed to catch what science can't predict."
Dahan-Farkas adds, "There is genuine and exciting science behind several of these compounds, but the evidence varies enormously from one peptide to another."
In five to 10 years, Naicker predicts the public health system will face a slow-building, hard-to-attribute wave of fallout: unexplained organ dysfunction, injection-site abscesses and unmapped multi-drug interactions.
The grey-market economy
Where consumer impatience meets regulatory friction, a lucrative grey market thrives:
Overseas synthesis factories: Chemical plants produce raw peptide powders in high-volume batches.
"Research" vendors: Storefronts re-bottle powders into vials, using "Not for Human Consumption" labels to dodge drug laws and mark up prices by up to 5,000%.
MedSpas and clinics: Wellness centres sell compounded peptides under costly "longevity protocols."
Influencer affiliates: Social media personalities drive sales to vendor sites for 10% to 30% kickbacks.
There is genuine science behind some peptides. There is also a widening gap between what has been demonstrated in clinical research and what is being promised online. For consumers, the central question is no longer simply whether a peptide is biologically interesting, but whether it has been properly tested, manufactured and shown to be safe and effective in humans.
Meanwhile many consumers believe they are buying an early ticket to the future of medicine. In reality, they may very well be absorbing the bulk of the health risk while an unregulated shadow market reaps all of the profit.
alyssia.birjalal@nationalmg.co.za